Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials

This clinical trial gathers information about adolescents and young adults (AYA) and patient reported outcomes data in Eastern Cooperative Oncology Group (ECOG)-American College of Radiology Imaging Network (ACRIN) trials to improve the collection of AYA patient reported outcomes. This study may help doctors understand the needs of adolescent and young adult cancer patients.

Inclusion Criteria: * Patient must be \>= 18 years and =\< 39 years of age at registration * Patient must have a histologically confirmed diagnosis of primary cancer of any stage within 12 weeks (84 days) at registration * Patient must not have a recurrence or second primary cancer * Patients must not have basal cell skin carcinoma * Patient must have received, be currently receiving or planning to receive treatment for cancer, including surgery and/or chemotherapy and/or radiation therapy * Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status 0-3 * Patient must have a life expectancy \> 24 months * Patient must be able to complete questionnaires in English or in Spanish * Patient must have internet access through computer, tablet, or smartphone * Patient must have an email address * Patient must have a mobile phone able with text messaging capabilities * Patient must be able to accurately provide self-report data (e.g. per clinical judgment, cognitive function is intact) * Patient must be able to provide informed consent * Participation in clinical trials is not an exclusionary criterion in EAQ202. Patients may be dually enrolled in EAQ202 as well as in therapeutic trials, including those involving checkpoint inhibitors * NOTE: We understand that some therapeutic trials may also collect PRO data (e.g., the cross-National Clinical Trials Network \[NCTN\] S1826 study in which ECOG-ACRIN is participating), thus creating a potential for overburdening patients. We will be attentive to informing all patients of this potential overburdening as they consider a voluntary decision to register for EAQ202. We will coordinate with the PRO chair(s) of the therapeutic studies to ensure that the integrity of the PRO analyses be preserved